Bonus BioGroup Ltd.
BBIXF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.22 | -0.06 | 0.00 |
| FCF Yield | -1,711.51% | -5.20% | -8.77% | -3.88% |
| EV / EBITDA | -1.59 | -15.78 | -10.85 | -25.60 |
| Quality | ||||
| ROIC | -77.33% | -77.33% | -32.93% | -34.88% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.64 | 0.64 | 0.76 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 9.52% | 24.39% | 3.95% |
| Safety | ||||
| Net Debt / EBITDA | -1.54 | -1.54 | -0.67 | -0.30 |
| Interest Coverage | -30.13 | -30.13 | -32.46 | -22.71 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |